A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Area Under the Concentration-time Curve (AUC) over the Dosing Interval at Cycle 1

Timeframe: At the end of Cycle 1 (each cycle is 21 days)

Defined as AUC calculated in Cycle 1 based on intensive PK assessment

Area Under the Concentration-time Curve (AUC) over the Dosing Interval at Cycle 6

Timeframe: At the end of Cycle 6 (each cycle is 21 days)

Defined as AUC calculated in Cycle 6 based on intensive PK assessment

Disease-free Survival

Timeframe: From the date of randomization until the date of disease recurrence, occurrence of new primary NSCLC, or death of any cause, whichever occurs first, assessed up to Week 55

Defined as the time from the date of randomization until the date of disease recurrence, occurrence of new primary NSCLC, or death of any cause, whichever occurs first.

Overall Survival

Timeframe: From the date of randomization until the date of death of any cause, assessed up to Week 55

Defined as the time from the date of randomization until the date of death of any cause.